PNC Financial Services Group
RAPP icon

PNC Financial Services Group’s Rapport Therapeutics RAPP Stock Holding History

PNC Financial Services Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.29K Buy
98
+50
+104% +$2.16K ﹤0.01% 4668
2026
Q2 		$2K Hold
48
– – ﹤0.01% 4680
2026
Q1 		$1.5K Buy
48
+1
+2% +$28 ﹤0.01% 4664
2025
Q4 		$1.43K Sell
47
-5
-10% -$138 ﹤0.01% 4608
2025
Q3 		$1.54K Buy
+52
New +$928 ﹤0.01% 4570

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

PNC Financial Services Group's RAPP Position: Q3 2026 in Review

PNC Financial Services Group increased its Rapport Therapeutics (RAPP) stake by 104% in Q3 2026, buying an estimated $2.16K and bringing the position to 98 shares worth $3.29K. The position accounts for ﹤0.01% of the portfolio, ranked #4668.

PNC Financial Services Group first reported a position in RAPP in Q3 2025 and has held it in 5 quarters since. 67 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • PNC Financial Services Group held 98 shares of Rapport Therapeutics worth $3.29K as of Q3 2026.
  • PNC Financial Services Group bought 50 Rapport Therapeutics shares in Q3 2026, an estimated $2.16K.
  • Rapport Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4668 holding.
  • PNC Financial Services Group first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 67 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.